Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Summary

The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)

Timeline

Start

2024-12-20

Primary completion

2026-12-30

Completion

2029-06-30

Drugs

Indications